Research

*June 2020* Patients with small cell lung cancer (SCLC) with brain metastases saw similar if not slightly better survival when treated with stereotactic radiosurgery (SRS) compared with standard-of-care whole brain radiotherapy (WBRT), findings from the FIRE-SCLC study indicated. Read more.

*July 2020* Dr. Roy Herbst addresses this question in a video. Watch it here.

*July 2020* In the trial, 49 patients enrolled between August 2016 and May 2018 at Memorial Sloan Kettering Cancer Center received osimertinib at 80 mg daily and bevacizumab at 15 mg/kg once every 3 weeks, the maximum-tolerated dose identified in the phase I portion of the trial. The primary outcome…

*May 2020* The first lung cancer patient to be treated with a new type of immunotherapy involving the re-engineering of a patient's T cells, known as TCR T-cell therapy, took place at Winship Cancer Institute of Emory University (Winship) on May 7, 2020. The Winship patient is enrolled on a…

*May 2020* In this video, Dr. Carbone discusses acquired resistance to osimertinib in NSCLC.

*May 2020* The study results indicated clinical efficacy against central nervous system metastases in a cohort of patients. Almonertinib also displayed an overall favorable safety profile. Clinical benefit was observed with almonertinib (HS-10296) as treatment of patients with EGFR T790M-mutant non–small cell lung cancer (NSCLC) who progressed on previous EGFR tyrosine kinase inhibitors…

*June 2020* Webcast: Join the EGFR Registers and top lung cancer specialists discuss facts vs myths in lung cancer treatment. A must-see for EGFR lung cancer patients/survivors. Register and watch it here.

*June 2020* Webcast: Listen to top experts in lung cancer discuss and interpret the latest research from ASCO 2020 with EGFR Resisters co-founders, Ivy Elkins and Jill Feldman.  Very informative and a must-watch for lung cancer survivors. Register and watch it here.

*March 2020* A biopsy sample of tissue often is tested for specific genetic variations (also referred to as mutations) that may have a targeted inhibitor that represents a clear optimal treatment for that cancer. However, it may not be possible to get enough tissue from the tumor to do these studies.…

*March 2020* Checkpoint inhibitors and next-generation TKIs have demonstrated improved survival outcomes in patients with non–small cell lung cancer (NSCLC); however, ongoing research efforts are looking to build upon the benefits with combination strategies and prevent acquired resistance to treatment, explained David P. Carbone, MD, PhD. “It's an incredibly exciting…